Abstract:Bo Feng, 1, &ast Xu Dong, 1, &ast Zhen Liu, 2 Jie Zhang, 3 Hongyu Liu, 1 Yuan Xu 1 1 Department of Pharmacy, The Affiliated Hospital of Yangzhou University, Yangzhou, People's Republic of China; 2 Department of Neurology, The Affiliated Hospital of Yangzhou University, Yangzhou, People's Republic of China; 3 Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hongyu Liu; Yuan Xu, Department of Pharmacy, The Affiliated Hospital of Yangzhou University, Yangzhou, People's Republic of China, Email ; Purpose: Protein tyrosine phosphatases (PTPs) play an essential way in diseases including cancer, obesity, diabetes and autoimmune disorders. As a member of PTPs, low molecular weight PTP (LMPTP) has been a well-recognized anti-insulin resistance target in obesity. However, the number of reported LMPTP inhibitors is limited. Our research aims to discover a novel LMPTP inhibitor and evaluate its biological activity against insulin resistance. Methods: A virtual screening pipeline based on the X-ray co-crystal complex of LMPTP was constructed. Enzyme inhibition assay and cellular bioassay were used to evaluate the activity of screened compounds. Results: The screening pipeline rendered 15 potential hits from Specs chemical library. Enzyme inhibition assay identified compound F9 (AN-465/41163730) as a potential LMPTP inhibitor with a K i value of 21.5 ± 7.3 μM. Cellular bioassay showed F9 could effectively increase the glucose consumption of HepG2 cells as a result of releasing insulin resistance by regulating PI3K-Akt pathway. Conclusion: In summary, this study presents a versatile virtual screening pipeline for potential LMPTP inhibitor discovery and provides a novel-scaffold lead compound that is worthy of further modification to get more potent LMPTP inhibitors. Graphical Keywords: virtual screening, low molecular weight protein tyrosine phosphatase, LMPTP inhibitor, insulin resistance, molecular docking Graphical Protein tyrosine phosphorylation, regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is essential for numerous cellular processes like cell growth, differentiation, migration and survival. 1,2 Selective modulation of the signaling pathway involved in protein tyrosine phosphorylation has been an effective strategy for therapeutic intervention due to the successful clinical application of various PTK inhibitors. As counterparts of PTKs, PTPs have attracted more attention as the potential therapeutic targets for different diseases, including cancer, 3 obesity, 4 diabetes 5,6 and autoimmune disorders. 7 More than 100 PTPs have been discovered, and most of them share the similar active site sequence C(X)5R(S/T), which specifically binds the phosphoryl group of their substrates. 8,9 Low molecular protein tyrosine phosphatase (LMPTP) is the only member of the Class II subfamily of PTPs besides the recently reclassified SSU72. 10 Abundant studies suggest that LMPTP is a potential target for alleviating insulin resistance in obesity and diabetes. 11,12 LMPTP knockdown by antisense oligonucleotides effectively decreases insulin resistance in diet-induced obese (DIO) mice by enhancing insulin receptor phosphorylation. 13 Given the insulin receptor dephosphorylating function of LMPTP, developing small molecular inhibitors of LMPTP as insulin sensitizers has attracted considerable interest from researchers. 14 However, most reported inhibitors, containing phosphate 15 (Figure 1a), carboxylic 16 (Figure 1b) and sulfonic group 17 (Figure 1c) targeting LMPTP active site exhibit poor selectivity and druggability because of the highly charged and homologous characteristics of LMPTP. 18,19 Hence, developing non-active site inhibitors would be the solution to the problems above-mentioned (Figure 1d and e). 20,21 Figure 1 The representative LMPTP inhibitors. ( a – c ) Representative active site inhibitors of LMPTP; ( d and e ) representative non-active site inhibitors of LMPTP. Herein, a virtual screening pipeline was developed based on the X-ray structure of LMPTP complexes, 20 and a novel LMPTP non-active site inhibitor was identified through this method. Enzyme inhibition assay found that the compound displayed a moderate LMPTP in -Abstract Truncated-

Fragment-Based Discovery of Novel VE-PTP Inhibitors Using Orthogonal Biophysical Techniques.

Identification and Structure-Function Analyses of an Allosteric Inhibitor of the Tyrosine Phosphatase PTPN22.

Structure-Based Discovery of Small Molecule Inhibitors Targeted to Protein Tyrosine Phosphatase 1B

Discovery and Sar of A Novel Selective and Orally Bioavailable Nonpeptide Classical Competitive Inhibitor Class of Protein-Tyrosine Phosphatase 1B

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Integrated use of ligand and structure-based virtual screening, molecular dynamics, free energy calculation and ADME prediction for the identification of potential PTP1B inhibitors

Discovery of Inhibitors Targeting Protein Tyrosine Phosphatase 1B Using a Combined Virtual Screening Approach

Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2)

Identification of a Benzo Imidazole Thiazole Derivative As the Specific Irreversible Inhibitor of Protein Tyrosine Phosphatase.

An expanded trove of fragment-bound structures for the allosteric enzyme PTP1B from computational reanalysis of large-scale crystallographic data

Structure-Based Design and Synthesis of Small Molecule Protein-Tyrosine Phosphatase 1b Inhibitors

Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology

Proteomic Identification of Protein Tyrosine Phosphatase and Substrate Interactions in Living Mammalian Cells by Genetic Encoding of Irreversible Enzyme Inhibitors

Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors

Discovering the Distinct Inhibitory Effects Between C4-epimeric Glycosyl Amino Acids: New Insight into the Development of Protein Tyrosine Phosphatase Inhibitors

Virtual Screening and Biological Evaluation of Novel Low Molecular Weight Protein Tyrosine Phosphatase Inhibitor for the Treatment of Insulin Resistance

Discovery of Novel PTP1B Inhibitors by High-throughput Virtual Screening

Crystal Structure of PTP1B Complexed with a Potent and Selective Bidentate Inhibitor

Screening and identification of potential PTP1B allosteric inhibitors using in silico and in vitro approaches

Design and Biological Evaluation of Novel Imidazolyl Flavonoids As Potent and Selective Protein Tyrosine Phosphatase Inhibitors.

Development of Novel Phosphonodifluoromethyl-Containing Phosphotyrosine Mimetics and a First-In-Class, Potent, Selective, and Bioavailable Inhibitor of Human CDC14 Phosphatases